ReutersReuters

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

RefinitivBacaan kurang dari 1 minit

Cybin Inc CYBN:

  • CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini